DIGESTION OF FOOD OXALATE

Information

  • Research Project
  • 6070186
  • ApplicationId
    6070186
  • Core Project Number
    R43DK057307
  • Full Project Number
    1R43DK057307-01
  • Serial Number
    57307
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/15/2000 - 25 years ago
  • Project End Date
    1/31/2001 - 24 years ago
  • Program Officer Name
    NYBERG, LEROY M.
  • Budget Start Date
    2/15/2000 - 25 years ago
  • Budget End Date
    1/31/2001 - 24 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/11/2000 - 25 years ago

DIGESTION OF FOOD OXALATE

The absorption of dietary oxalate makes a significant contribution to the amount of oxalate excreted in urine and thus plays an important role in the development of calcium oxalate kidney stones. Current therapies to limit this risk factor are low oxalate diets and dietary supplementation with calcium. These approaches are only partially effective and a more efficacious therapy is required. Removal of oxalate from ingested foods by digestion is the approach to be evaluated in this research proposal. The efficiencies of oxalate degrading enzymes and oxalate -degrading bacteria in digesting the bioavailable oxalate in spinach and bread will be investigated in vitro. The bacteria used will be Oxalobacter formigenes, a normal part of the colonic flora in humans that uses oxalate as its sole source of carbon. The enzymes examined will include oxalate oxidase, an O2-requiring enzyme isolated from sugar beet, and the oxalate degrading enzymes from Oxalobacter formigenes, which do not require O2. The efficiency of these systems in degrading oxalate, singly or in combination will be evaluated using capillary electrophoresis and a method developed for measuring food oxalate. PROPOSED COMMERCIAL APPLICATION: Urolithiasis is a common disease with a few therapies that are effective in eliminating recurrences in susceptible individuals. This there is a large market for a product that can reduce urinary oxalate excretion that could potentially benefit all calcium oxalate stone formers. The proposed therapy would be a supplement to be taken with meals that digested oxalate before it could be absorbed.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IXION BIOTECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
    957419716
  • Organization City
    ALACHUA
  • Organization State
    FL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    32615
  • Organization District
    UNITED STATES